NASDAQ:CRTX

Cortexyme News Headlines

$63.22
+6.18 (+10.83 %)
(As of 08/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$57.22
$64.12
50-Day Range
$41.37
$64.49
52-Week Range
$26.66
$66.13
Volume163,931 shs
Average Volume248,915 shs
Market Capitalization$1.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.76

Cortexyme (NASDAQ CRTX) News Headlines Today

SourceHeadline
Cortexyme to Present at Canaccord Genuity s 41st Annual Growth Conference on August 11th - Business WireCortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th - Business Wire
businesswire.com - August 4 at 6:58 PM
Cortexyme (NASDAQ:CRTX) Shares Gap Up to $57.04Cortexyme (NASDAQ:CRTX) Shares Gap Up to $57.04
americanbankingnews.com - August 4 at 12:36 PM
Cortexyme to Present at Canaccord Genuity s 41st Annual Growth Conference on August 11thCortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
finance.yahoo.com - August 4 at 8:56 AM
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimers Disease at AAIC 2021 - Business WireCortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer's Disease at AAIC 2021 - Business Wire
businesswire.com - July 26 at 2:04 PM
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
finance.yahoo.com - July 26 at 2:04 PM
Cortexyme (NASDAQ:CRTX) Trading Down 6.5%Cortexyme (NASDAQ:CRTX) Trading Down 6.5%
americanbankingnews.com - July 26 at 12:45 PM
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Yahoo FinanceCortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Yahoo Finance
finance.yahoo.com - July 25 at 12:03 AM
AAIC 2021: What to look for at Alzheimers biggest annual conference - Seeking AlphaAAIC 2021: What to look for at Alzheimer's biggest annual conference - Seeking Alpha
seekingalpha.com - July 24 at 6:52 PM
Comparing Cortexyme (NASDAQ:CRTX) & ADMA Biologics (NASDAQ:ADMA)Comparing Cortexyme (NASDAQ:CRTX) & ADMA Biologics (NASDAQ:ADMA)
americanbankingnews.com - July 23 at 5:12 PM
Cortexyme Selects 3CLpro Inhibitor COR803 For Treatment Of Coronavirus Infection - BenzingaCortexyme Selects 3CLpro Inhibitor COR803 For Treatment Of Coronavirus Infection - Benzinga
benzinga.com - July 23 at 12:57 PM
Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate - Markets InsiderCortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate - Markets Insider
markets.businessinsider.com - July 23 at 12:57 PM
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Business WireCortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Business Wire
businesswire.com - July 23 at 12:57 PM
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus InfectionCortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
finance.yahoo.com - July 23 at 12:57 PM
Contrasting Cortexyme (NASDAQ:CRTX) and Novavax (NASDAQ:NVAX)Contrasting Cortexyme (NASDAQ:CRTX) and Novavax (NASDAQ:NVAX)
americanbankingnews.com - July 22 at 9:12 PM
Cortexyme (NASDAQ:CRTX) Sets New 52-Week High at $62.06Cortexyme (NASDAQ:CRTX) Sets New 52-Week High at $62.06
americanbankingnews.com - July 22 at 10:39 AM
Cortexyme to Present New Data at AAIC 2021 - Yahoo FinanceCortexyme to Present New Data at AAIC 2021 - Yahoo Finance
finance.yahoo.com - July 22 at 8:28 AM
Cortexyme to Present New Data at AAIC 2021Cortexyme to Present New Data at AAIC 2021
finance.yahoo.com - July 22 at 8:28 AM
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 - Yahoo FinanceCortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 - Yahoo Finance
finance.yahoo.com - July 21 at 2:17 PM
Cortexyme (NASDAQ:CRTX) Shares Gap Down to $57.76Cortexyme (NASDAQ:CRTX) Shares Gap Down to $57.76
americanbankingnews.com - July 21 at 11:12 AM
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 - Business WireCortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 - Business Wire
businesswire.com - July 21 at 8:39 AM
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
finance.yahoo.com - July 21 at 8:39 AM
Cortexyme to Host Symposium at AAIC 2021 - Yahoo FinanceCortexyme to Host Symposium at AAIC 2021 - Yahoo Finance
finance.yahoo.com - July 19 at 9:56 AM
Cortexyme to Host Symposium at AAIC 2021Cortexyme to Host Symposium at AAIC 2021
finance.yahoo.com - July 19 at 9:56 AM
Cortexyme (NASDAQ:CRTX) Stock Price Up 4.3%Cortexyme (NASDAQ:CRTX) Stock Price Up 4.3%
americanbankingnews.com - July 16 at 1:22 PM
Traders Buy Large Volume of Call Options on Cortexyme (NASDAQ:CRTX)Traders Buy Large Volume of Call Options on Cortexyme (NASDAQ:CRTX)
americanbankingnews.com - July 14 at 4:16 PM
Cortexyme (NASDAQ:CRTX) Stock Price Down 6%Cortexyme (NASDAQ:CRTX) Stock Price Down 6%
americanbankingnews.com - July 14 at 12:48 PM
Cidara Therapeutics (NASDAQ:CDTX) and Cortexyme (NASDAQ:CRTX) Head to Head SurveyCidara Therapeutics (NASDAQ:CDTX) and Cortexyme (NASDAQ:CRTX) Head to Head Survey
americanbankingnews.com - July 12 at 11:18 PM
Peter Thiels audacious early-stage science Breakout Labs winding down - San Francisco Business Times - San Francisco Business TimesPeter Thiel's 'audacious' early-stage science Breakout Labs winding down - San Francisco Business Times - San Francisco Business Times
bizjournals.com - July 8 at 7:20 PM
Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat - Yahoo FinanceCortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat - Yahoo Finance
finance.yahoo.com - July 8 at 7:20 PM
Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat - Business WireCortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat - Business Wire
businesswire.com - July 8 at 9:19 AM
Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on AtuzaginstatCortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat
finance.yahoo.com - July 8 at 9:19 AM
Most and Least Profitable Short Sales in June and 10 Squeezable Stocks for July - 24/7 Wall St.Most and Least Profitable Short Sales in June and 10 Squeezable Stocks for July - 24/7 Wall St.
247wallst.com - July 6 at 1:01 PM
Stocks Flashing Renewed Technical Strength: Cortexyme - Investors Business DailyStocks Flashing Renewed Technical Strength: Cortexyme - Investor's Business Daily
investors.com - June 21 at 2:07 PM
Stocks With Rising Relative Strength: Cortexyme - Investors Business DailyStocks With Rising Relative Strength: Cortexyme - Investor's Business Daily
investors.com - June 18 at 12:48 PM
Alzheimers Disease Market Set To Witness Spells of Growth in the 7MM By 2030, Foresees DelveInsight - Yahoo FinanceAlzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2030, Foresees DelveInsight - Yahoo Finance
finance.yahoo.com - June 16 at 2:07 PM
Hedge Funds Are Dumping Cortexyme, Inc. (CRTX) - Yahoo FinanceHedge Funds Are Dumping Cortexyme, Inc. (CRTX) - Yahoo Finance
finance.yahoo.com - June 13 at 7:13 PM
Hedge Funds Are Dumping Cortexyme, Inc. (CRTX)Hedge Funds Are Dumping Cortexyme, Inc. (CRTX)
finance.yahoo.com - June 13 at 7:13 PM
For Alzheimers patient advocates, Biogens drug approval opens the door - Boston Business Journal - Boston Business JournalFor Alzheimer's patient advocates, Biogen's drug approval opens the door - Boston Business Journal - Boston Business Journal
bizjournals.com - June 10 at 7:54 AM
Were Not Very Worried About Cortexymes (NASDAQ:CRTX) Cash Burn Rate - NasdaqWe're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate - Nasdaq
nasdaq.com - June 8 at 5:24 PM
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting - Business WireCortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting - Business Wire
businesswire.com - June 1 at 8:37 AM
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual MeetingCortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting
finance.yahoo.com - June 1 at 8:37 AM
Cortexyme to Present at Investor Conferences in June 2021 - Yahoo Finance AustraliaCortexyme to Present at Investor Conferences in June 2021 - Yahoo Finance Australia
finance.yahoo.com - May 26 at 8:18 AM
Cortexyme to Present at Investor Conferences in June 2021Cortexyme to Present at Investor Conferences in June 2021
finance.yahoo.com - May 26 at 8:18 AM
Add Up The Pieces: XBI Could Be Worth $215 - NasdaqAdd Up The Pieces: XBI Could Be Worth $215 - Nasdaq
nasdaq.com - May 13 at 12:38 PM
Cortexyme Inc (CRTX) CEO Casey Lynch Sold $1 million of Shares - Yahoo FinanceCortexyme Inc (CRTX) CEO Casey Lynch Sold $1 million of Shares - Yahoo Finance
finance.yahoo.com - May 13 at 2:00 AM
Cortexyme Provides Business Update and Reports First Quarter 2021 Results - Yahoo FinanceCortexyme Provides Business Update and Reports First Quarter 2021 Results - Yahoo Finance
finance.yahoo.com - May 12 at 9:00 PM
How Much Are Cortexyme, Inc. (NASDAQ:CRTX) Insiders Spending On Buying Shares? - Yahoo FinanceHow Much Are Cortexyme, Inc. (NASDAQ:CRTX) Insiders Spending On Buying Shares? - Yahoo Finance
finance.yahoo.com - May 10 at 9:34 PM
Cortexyme EPS beats by $0.02 - Seeking AlphaCortexyme EPS beats by $0.02 - Seeking Alpha
seekingalpha.com - May 10 at 9:34 PM
Cortexyme Provides Business Update and Reports First Quarter 2021 ResultsCortexyme Provides Business Update and Reports First Quarter 2021 Results
finance.yahoo.com - May 10 at 4:33 PM
How Much Are Cortexyme, Inc. (NASDAQ:CRTX) Insiders Spending On Buying Shares?How Much Are Cortexyme, Inc. (NASDAQ:CRTX) Insiders Spending On Buying Shares?
finance.yahoo.com - May 9 at 11:45 AM
This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.